Johnson & Johnson Acquires Intra-Cellular Therapies in $14.6 Billion Deal
Overview of the Deal Acquirer: Johnson & Johnson Target: Intra-Cellular Therapies Total Transaction Size: $14.6 billion Price Per Share: $132 (40% premium to recent closing price) Announcement Date: January